LYEL
Lyell Immunopharma
Obter previsão
Obtenha previsões de ações IA no seu dispositivo
Sobre esta empresa
Lyell Immunopharma specializes in cell therapy, focusing on the reprogramming of T-lymphocytes for the treatment of solid tumors. The company’s technologies are applicable regardless of biological targets and their associated pathways, and are utilized in chimeric antigen receptor (CAR) T-cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, and T-cell receptor (TCR) therapy. Lyell Immunopharma is currently developing a pipeline of products designed to deliver comprehensive therapeutic effects across various forms of solid tumors that are difficult to treat.
Obtenha previsões de ações IA agora
Baixe nosso app para previsões de ações IA em tempo real
